Buy this domain?
Click Here

July 2019
M T W T F S S
     
1234567
891011121314
15161718192021
22232425262728
293031  

Search

ato.my
Graft-versus-host disease
Graft-versus-host disease (GvHD) is a medical complication following the receipt of transplanted tissue from a genetically different person. GvHD is commonly
Transfusion-associated graft-versus-host disease
Transfusion-associated graft-versus-host disease (TA-GvHD) is a rare complication of blood transfusion, in which the immunologically competent donor T
Hematopoietic stem cell transplantation
radiation or chemotherapy before the transplantation. Infection and graft-versus-host disease are major complications of allogeneic HSCT. Hematopoietic stem
Anti-thymocyte globulin
is frequently given at the time of the transplant to prevent graft-versus-host disease, although many European centers prefer to reserve its use for
Transplant rejection
mediate allograft rejection via the CD4 and CD8 T cells Graft-versus-host disease Graft-versus-tumor effect Immunosuppression Frohn, C; Fricke, L; Puchta
Graft-versus-tumor effect
myeloma and possibly breast cancer. It is closely linked with graft-versus-host disease (GvHD), as the underlying principle of alloimmunity is the same
Alemtuzumab
(no controls) with severe steroid-resistant acute intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (HSCT)
Thymus transplantation
Theoretically, thymus transplantation could cause two types of graft-versus-host disease (GVHD): First, it could cause a donor T cell-related GVHD, because
Cyclophosphamide
people who are ill-suited for autologous stem cell transplant. Graft-versus-host disease (GVHD) is a major barrier for allogeneic stem cell transplant
Mesoblast
medications, health care services and lost productivity at work. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone